Urinary retention and mydriasis secondary to topical glycopyrronium for axillary hyperhidrosis
American Journal of Health-System Pharmacy · 2023
DOI: 10.1093/ajhp/zxad141 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Health-System Pharmacy, 2023. Verfasst von Holly Hoshall Green und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA. Hauptthemen laut MEDLINE: Mydriasis, Urinary Retention, Hyperhidrosis, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Purpose
Glycopyrronium, also known as glycopyrrolate, is an antimuscarinic competitive inhibitor of acetylcholine widely utilized topically for its anticholinergic properties in dermatology. A single topical glycopyrronium tosylate (GT) formulation is available on the market, and prescription of this medication has become increasingly popular among dermatologists. This medication has a relatively notable adverse effect profile and carries risks that patients need to be counseled on before initiation. Summary A 22-year-old female presented to our emergency department (ED) with a chief complaint of difficulty urinating for 48 hours and blurred vision for 2 weeks. Over the course of a week, she visited the ED once and urgent care multiple times due to complications associated with combination use of GT and cetirizine. Although these clinical effects were reversible, the patient impact in our case was profound given the time, cost, and invasive nature of these visits.
Conclusion
The notable adverse effects of GT should be considered when prescribing this agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.
- Denver Health and Hospital Authority, Denver, CO.
- Department of Emergency Medicine, University of Colorado Anschutz, Aurora, CO, USA.
- Department of Emergency Medicine, Rocky Mountain Poison and Drug Safety, Denver, CO, USA.
Zitieren
APA
Green, H. H., Ray, L., Buchanan, J., & Matsler, N. (2023). Urinary retention and mydriasis secondary to topical glycopyrronium for axillary hyperhidrosis. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxad141
Vancouver
Green HH, Ray L, Buchanan J, Matsler N. Urinary retention and mydriasis secondary to topical glycopyrronium for axillary hyperhidrosis. American Journal of Health-System Pharmacy. 2023. doi:10.1093/ajhp/zxad141
BibTeX
@article{Green2023,
author = {Green, Holly Hoshall and Ray, Lance and Buchanan, Jennie and Matsler, Nikolaus},
title = {Urinary retention and mydriasis secondary to topical glycopyrronium for axillary hyperhidrosis},
journal = {American Journal of Health-System Pharmacy},
year = {2023},
doi = {10.1093/ajhp/zxad141}
}
EUVIMED